Comprehensive Financial Consultants Institutional Inc. Invests $780,000 in DexCom, Inc. (NASDAQ:DXCM)

Comprehensive Financial Consultants Institutional Inc. bought a new position in DexCom, Inc. (NASDAQ:DXCM) during the first quarter, HoldingsChannel.com reports. The fund bought 5,626 shares of the medical device company’s stock, valued at approximately $780,000.

Other institutional investors have also recently modified their holdings of the company. Stableford Capital II LLC lifted its holdings in DexCom by 2.1% in the 4th quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock worth $563,000 after purchasing an additional 88 shares in the last quarter. D Orazio & Associates Inc. increased its stake in DexCom by 0.8% in the 4th quarter. D Orazio & Associates Inc. now owns 12,366 shares of the medical device company’s stock worth $1,534,000 after acquiring an additional 93 shares during the last quarter. Gulf International Bank UK Ltd increased its stake in DexCom by 0.3% in the 1st quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock worth $4,448,000 after acquiring an additional 93 shares during the last quarter. EverSource Wealth Advisors LLC increased its stake in DexCom by 10.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the medical device company’s stock worth $133,000 after acquiring an additional 98 shares during the last quarter. Finally, Harbor Investment Advisory LLC increased its stake in DexCom by 13.1% in the 1st quarter. Harbor Investment Advisory LLC now owns 864 shares of the medical device company’s stock worth $120,000 after acquiring an additional 100 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Stock Down 0.1 %

Shares of NASDAQ DXCM traded down $0.13 during mid-day trading on Tuesday, reaching $110.84. 1,290,425 shares of the company were exchanged, compared to its average volume of 2,901,135. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. The stock has a market cap of $44.08 billion, a price-to-earnings ratio of 71.51, a P/E/G ratio of 2.78 and a beta of 1.16. DexCom, Inc. has a 1 year low of $74.75 and a 1 year high of $142.00. The firm has a 50-day moving average of $120.73 and a 200 day moving average of $125.30.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. On average, research analysts expect that DexCom, Inc. will post 1.78 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on DXCM shares. UBS Group lifted their price objective on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Citigroup boosted their target price on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Redburn Atlantic initiated coverage on DexCom in a research report on Thursday, May 30th. They set a “neutral” rating and a $130.00 target price on the stock. Royal Bank of Canada initiated coverage on DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 target price on the stock. Finally, StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research report on Monday, June 10th. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $140.33.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 427 shares of the company’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $49,126.35. Following the transaction, the executive vice president now directly owns 75,877 shares of the company’s stock, valued at approximately $8,729,648.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, EVP Matthew Vincent Dolan sold 1,990 shares of the company’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $137.81, for a total transaction of $274,241.90. Following the transaction, the executive vice president now directly owns 42,377 shares of the company’s stock, valued at approximately $5,839,974.37. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Sadie Stern sold 427 shares of the company’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $115.05, for a total value of $49,126.35. Following the transaction, the executive vice president now directly owns 75,877 shares in the company, valued at $8,729,648.85. The disclosure for this sale can be found here. Insiders sold 6,102 shares of company stock worth $755,103 in the last three months. 0.30% of the stock is owned by insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.